Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Patnaik, A
Beeram, M
de Bono, JS
Mita, A
Chu, SC
Rowinsky, EK
Schwartz, G
O'Rourke, P
Takimoto, CH
Tolcher, AW
机构：
[1] CTRC, Inst Drug Dev, San Antonio, TX USA
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Brooke Army Med Ctr, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135S / 135S
页数：1
相关论文
共 37 条
  • [11] Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
    S. Tjulandin
    V. Moiseyenko
    V. Semiglazov
    G. Manikhas
    M. Learoyd
    A. Saunders
    M. Stuart
    U. Keilholz
    Investigational New Drugs, 2014, 32 : 145 - 153
  • [12] Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
    Tjulandin, S.
    Moiseyenko, V.
    Semiglazov, V.
    Manikhas, G.
    Learoyd, M.
    Saunders, A.
    Stuart, M.
    Keilholz, U.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 145 - 153
  • [13] A PHASE I STUDY OF DAILY AFATINIB, AN IRREVERSIBLE ERBB FAMILY BLOCKER, COMBINED WITH WEEKLY PACLITAXEL AND 2-WEEKLY BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMOURS
    Enting, D.
    Ang, J. E.
    O'Hanlon-Brown, C.
    Kristeleit, R.
    Uttenreuther-Fischer, M.
    Pemberton, K.
    Pelling, K.
    Schnell, D.
    de Bono, J. S.
    Spicer, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 161 - 161
  • [14] Phase I and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors.
    Marshall, JL
    Ramalingam, S
    Hwang, JJ
    Ramanathan, R
    Malik, S
    Egorin, M
    Hannah, A
    Cropp, GF
    Johnson, RG
    Belani, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 145S - 145S
  • [15] Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies
    Patnaik, A
    Goetz, A
    Hammond, LA
    Tolcher, AW
    Schwartz, G
    Hill, M
    Zitelli, A
    Wood, D
    Nadler, P
    Rowinsky, EK
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S54 - S54
  • [16] Phase I and pharmacokinetics (PK) study of RPR 116258A given as 1-hour infusion in patients (pts) with advanced solid tumors.
    Lortholary, A
    Pierga, JY
    Delva, R
    Girre, V
    Gamelin, E
    Terpereau, A
    Crespel, G
    Pouillart, P
    Fontaine, H
    Semiond, D
    Pérard, D
    Besenval, M
    Diéras, V
    CLINICAL CANCER RESEARCH, 2000, 6 : 4579S - 4580S
  • [17] Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).
    Moreno, Lucas
    Casanova, Michela
    Chisholm, Julia C.
    Berlanga, Pablo
    Chastagner, Pascal B.
    Baruchel, Sylvain
    Manzitti, Carla
    Melcon, Soledad Gallego
    Gerber, Nicolas U.
    Bisogno, Gianni
    Fagioli, Franca
    Geoerger, Birgit
    Bender, Julia Glade
    Aerts, Isabelle
    Bergeron, Christophe
    Hingorani, Pooja
    Elias, Ileana
    Simcock, Mathew
    Slepetis, Ruta
    Vassal, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [18] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
    Moldovan, C.
    Soria, J.
    LoRusso, P.
    Guthrie, T.
    Song, C.
    Nguyen, L. T.
    Martini, J.
    Infante, J. R.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [19] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
    Traynor, A. M.
    Kurzrock, R.
    Bailey, H. H.
    Attia, S.
    Scheffold, C.
    van Leeuwen, B.
    Wu, B.
    Falchook, G. S.
    Moulder, S. L.
    Wheler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [20] Phase I and pharmacokinetics study (PK) study of the safety and tolerability of the dual EGFR1/ErbB2 tyrosine kinase (TK) inhibitor GW572016 (GW) in combination with capecitabine (C) in patients with advanced solid malignancies.
    Mita, MM
    Chu, QS
    De Bono, J
    Schwartz, G
    Curtright, J
    Hammond, LA
    Patnaik, A
    Garrison, M
    Tolcher, A
    Versola, M
    Koch, K
    Stead, A
    Smith, DA
    Pandite, L
    Rowinsky, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6100S - 6100S
1234